Braveheart Bio
PublicBraveheart Bio is now publicly traded
The data on this page reflects Braveheart Bio's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Went Public
Aug 5, 2026
Last Round
Series A
Nov 5, 2025
Total Funding Raised
$567.5M
Company Overview
Braveheart Bio is a biotechnology company developing novel therapeutics for hypertrophic cardiomyopathy and related cardiovascular conditions.
AI Layer
Non-AI
Keywords
Braveheart Bio Comparables
Compare Braveheart Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Zhejiang Jixing Auto Parts Co., Ltd. | 81% | |
| Bristol Myers Squibb | 80% | |
| Cytokinetics, Incorporated | 79% |
Braveheart Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| IPO | Aug 5, 2026 | ||||
| Series A | Nov 5, 2025 |
Key People
Founding team and executive leadership
Braveheart Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Andreessen Horowitz | Series A |
| Enavate Sciences | Series A |
| Forbion | Series A |
| Fidelity Management & Research Company | IPO |
| OrbiMed | Series A |
| Frazier Life Sciences | Series A |
Recent news
Latest coverage and updates
- is_developingSep 18, 2026
Braveheart is developing therapies for hypertrophic cardiomyopathy on Sep 19th '26.
- attends_eventSep 16, 2026
Braveheart will attend event Stifel Virtual Cardiometabolic Forum on Sep 30th '26.
- attends_eventSep 1, 2026
Braveheart will attend event Cantor Global Healthcare Conference on Sep 9th '26.
- receives_financingAug 6, 2026
Braveheart received financing of $383M in IPO on Aug 6th '26.
Braveheart Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request access